The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
NK Cells Recognize and Kill Human Glioblastoma Cells with Stem Cell-Like Properties
Abstract
In this study, cancer cells were isolated from tumor specimens of nine glioblastoma patients. Glioblastoma cells, cultured under suitable culture conditions, displayed markers typical of neural stem cells, were capable of partial multilineage differentiation in vitro, and gave origin to infiltrating tumors when orthotopically injected in NOD/SCID mice. These cells, although resistant to freshly isolated NK cells, were highly susceptible to lysis mediated by both allogeneic and autologous IL-2 (or IL-15)-activated NK cells. Indeed, all stem cell-cultured glioblastoma cells analyzed did not express protective amounts of HLA class I molecules, while expressing various ligands of activating NK receptors that triggered optimal NK cell cytotoxicity. Importantly, glioblastoma stem cells expressed high levels of PVR and Nectin-2, the ligands of DNAM-1-activating NK receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N. M., Pastorino, S., Purow, B. W., Christopher, N., Zhang, W., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.030 · Cited by 2,311
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma
Liu, G., Yuan, X., Zeng, Z., Tunici, P., Ng, H., Abdulkadir, I. R., Lu, L., Irvin, D., Black, K. L., & Yu, J. S. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-67 · Cited by 1,790
MHC class I molecules and kirs in human history, health and survival
Parham, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1570 · Cited by 1,203
Beier, D., Hau, P., Proescholdt, M., Lohmeier, A., Wischhusen, J., Oefner, P. J., Aigner, L., Brawanski, A., Bogdahn, U., & Beier, C. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4180 · Cited by 1,153
Bottino, C., Castriconi, R., Pende, D., Rivera, P., Nanni, M., Carnemolla, B., Cantoni, C., Grassi, J., Marcenaro, S., Reymond, N., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030788 · Cited by 875
Self-citationRECEPTORS FOR HLA CLASS-I MOLECULES IN HUMAN NATURAL KILLER CELLS
Moretta, A., Bottino, C., Vitale, M., Pende, D., Biassoni, R., Mingari, M. C., & Moretta, L. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.619 · Cited by 875
Self-citationCastriconi, R., Cantoni, C., Della Chiesa, M., Vitale, M., Marcenaro, E., Conte, R., Biassoni, R., Bottino, C., Moretta, L., & Moretta, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730640100 · Cited by 726
Self-citationCancer stem cells in nervous system tumors
Singh, S. K., Clarke, I. D., Hide, T., & Dirks, P. B. (2004) · Oncogene · doi:10.1038/sj.onc.1207946 · Cited by 569
CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells
Wang, J., Sakariassen, P. Ø., Tsinkalovsky, O., Immervoll, H., Bøe, S. O., Svendsen, A., Prestegarden, L., Røsland, G., Thorsen, F., Stuhr, L., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23130 · Cited by 567
Prospects for the use of NK cells in immunotherapy of human cancer
Ljunggren, H.-G., & Malmberg, K.-J. (2007) · Nature Reviews Immunology · doi:10.1038/nri2073 · Cited by 543
Pende, D., Rivera, P., Marcenaro, S., Chang, C., Biassoni, R., Conte, R., Kubin, M. Z., Cosman, D. J., Ferrone, S., Moretta, L., et al. (2002) · PubMed · Cited by 500
Self-citationCostello, R. T., Sivori, S., Marcenaro, E., Lafage-Pochitaloff, M., Mozziconacci, M.-J., Reviron, D., Gastaut, J.-A., Pende, D., Olive, D., & Moretta, A. (2002) · Blood · doi:10.1182/blood.v99.10.3661 · Cited by 500
Self-citationPromiscuity and the single receptor: NKG2D
Eagle, R. A., & Trowsdale, J. (2007) · Nature Reviews Immunology · doi:10.1038/nri2144 · Cited by 374
Pende, D., Spaggiari, G. M., Marcenaro, S., Martini, S., Rivera, P., Capobianco, A., Falco, M., Lanino, E., Pierri, I., Zambello, R., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3548 · Cited by 374
Self-citationFriese, M. A., Wischhusen, J., Wick, W., Weiler, M., Eisele, G., Steinle, A., & Weller, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1627 · Cited by 305
Natural Killer Cell-Mediated Killing of Freshly Isolated Neuroblastoma Cells
Castriconi, R., Dondero, A., Corrias, M. V., Lanino, E., Pende, D., Moretta, L., Bottino, C., & Moretta, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2682 · Cited by 259
Self-citationCellular ligands of activating NK receptors
Bottino, C., Castriconi, R., Moretta, L., & Moretta, A. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.02.007 · Cited by 255
Self-citationPellegatta, S., Poliani, P. L., Corno, D., Menghi, F., Ghielmetti, F., Suarez-Merino, B., Caldera, V., Nava, S., Ravanini, M., Facchetti, F., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2048 · Cited by 248
Self-citationCD155/PVR plays a key role in cell motility during tumor cell invasion and migration
Sloan, K. E., Eustace, B. K., Stewart, J. K., Zehetmeier, C., Torella, C., Simeone, M., Roy, J. E., Unger, C., Louis, D. N., Ilag, L. L., et al. (2004) · BMC Cancer · doi:10.1186/1471-2407-4-73 · Cited by 244
MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese, M. A., Platten, M., Lutz, S. Z., Naumann, U., Aulwurm, S., Bischof, F., Bühring, H. ‐., DICHGANS, J., Rammensee, H., Steinle, A., et al. (2003) · PubMed · Cited by 193
Wischhusen, J., Friese, M. A., Mittelbronn, M. G. A., Meyermann, R., & Weller, M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.6.523 · Cited by 157
Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor
Tahara‐Hanaoka, S., Shibuya, K., Kai, H., Miyamoto, A., Morikawa, Y., Ohkochi, N., Honda, S.-I., & Shibuya, A. (2005) · Blood · doi:10.1182/blood-2005-04-1684 · Cited by 152
Human neuroblastoma stem cells
Ross, R. A., & Spengler, B. A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.04.006 · Cited by 137
Human NK cells: from HLA class I‐specific killer Ig‐like receptors to the therapy of acute leukemias
Moretta, A., Locatelli, F., & Moretta, L. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00651.x · Cited by 128
Self-citationImmune selective pressure and HLA class I antigen defects in malignant lesions
Chang, C., & Ferrone, S. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0183-1 · Cited by 117
Lozupone, F., Pende, D., BURGIO, V. L., Castelli, C., Spada, M., Venditti, M., Luciani, F., Lugini, L., Federici, C., Ramoni, C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1501 · Cited by 90
Self-citationChansac, B. L. M., Moretta, A., Vergnon, I., Opolon, P., Lécluse, Y., Grunenwald, D. H., Kubin, M. Z., Soria, J., Chouaı̈b, S., & Mami‐Chouaib, F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5790 · Cited by 81
Self-citationNeoplastic stem cells: A novel therapeutic target in clinical oncology
Schulenburg, A., Ulrich-Pur, H., Thurnher, D., Erović, B. M., Florian, S., Sperr, W. R., Kalhs, P., Marian, B., Wrba, F., Zielinski, C. C., et al. (2006) · Cancer · doi:10.1002/cncr.22277 · Cited by 81
Castriconi, R., Dondero, A., Negri, F., et al. (2007) · European Journal of Immunology · doi:10.1002/eji.200737546 · Cited by 78
Self-citationMalignant glioma: Neuropathology and Neurobiology
Preusser, M., Haberler, C., & Hainfellner, J. A. (2006) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-006-0304-7 · Cited by 63
Valteau‐Couanet, D., Leboulaire, C., Maincent, K., Tournier, M., Hartmann, O., Bénard, J., Beaujean, F., Boccaccio, C., Zitvogel, L., & Angevin, E. (2002) · Blood · doi:10.1182/blood.v100.7.2554 · Cited by 56
Daga, A., Orengo, A. M., Gangemi, R. M. R., Marubbi, D., Perera, M., Comes, A., Ferrini, S., & Corte, G. (2007) · International Journal of Cancer · doi:10.1002/ijc.22901 · Cited by 45
Self-citationThe Innate Immune Response in the Central Nervous System and Its Role in Glioma Immune Surveillance
Friese, M. A., Steinle, A., & Weller, M. (2004) · Oncology Research and Treatment · doi:10.1159/000080371 · Cited by 32
Cited by
Control of Metastasis by NK Cells
López-Soto, A., Gonzalez, S., Smyth, M. J., & Galluzzi, L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.009 · Cited by 736
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors
Melaiu, O., Lucarini, V., Cifaldi, L., & Fruci, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03038 · Cited by 419
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Zhang, C., Burger, M. C., Jennewein, L., Genßler, S., Schönfeld, K., Zeiner, P., Hattingen, E., Harter, P. N., Mittelbronn, M., Tonn, T., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv375 · Cited by 388
Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma
DeCordova, S., Shastri, A., Tsolaki, A. G., Yasmin, H., Klein, L., Singh, S. K., & Kishore, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01402 · Cited by 346
Metadata
- Authors
- Castriconi, R., Daga, A., Dondero, A., Zona, G., Poliani, P. L., Melotti, A., Griffero, F., Marubbi, D., Spaziante, R., Bellora, F., Moretta, L., Moretta, A., Corte, G., & Bottino, C.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-03
- Volume
- 182
- Issue
- 6
- Pages
- 3530-3539
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2116376294
- Cited by
- 337
- References
- 35
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.